Brendan M. Weiss

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

S. Vincent Rajkumar, Meletios Α. Dimopoulos, Antonio Palumbo et al. · The Lancet Oncology · 2014 · 4.7K citations · Full text

Hematological Malignancy, Medicine, Hematology +7

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Jakub Krejcik, Tineke Casneuf, Inger S. Nijhof et al. · Blood · 2016 · 890 citations

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Sagar Lonial, Brendan M. Weiss, Saad Z. Usmani et al. · The Lancet · 2016 · 842 citations

Hematological Malignancy, Oncology, Daratumumab Monotherapy +6

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

Aaron P. Rapoport, Edward A. Stadtmauer, Gwendolyn Binder-Scholl et al. · Nature Medicine · 2015 · 832 citations · Full text

Cancer Immunosurveillance, Immunology, Tumor Immunity +9

B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

Adam D. Cohen, Alfred L. Garfall, Edward A. Stadtmauer et al. · Journal of Clinical Investigation · 2019 · 768 citations · Full text